

Imke Satzger

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/470503/publications.pdf>

Version: 2024-02-01

29
papers

1,760
citations

448610

19
h-index

563245

28
g-index

30
all docs

30
docs citations

30
times ranked

3420
citing authors

#	ARTICLE	IF	CITATIONS
1	Impact of American Joint Committee on Cancer 8th edition classification on staging and survival of patients with melanoma. <i>European Journal of Cancer</i> , 2019, 119, 18-29.	1.3	44
2	Melanoma-specific survival in patients with positive sentinel lymph nodes: Relevance of sentinel tumor burden. <i>European Journal of Cancer</i> , 2019, 123, 83-91.	1.3	15
3	Combination of denosumab and immune checkpoint inhibition: experience in 29 patients with metastatic melanoma and bone metastases. <i>Cancer Immunology, Immunotherapy</i> , 2019, 68, 1187-1194.	2.0	40
4	Risk Factors for Developing Nonmelanoma Skin Cancer after Lung Transplantation. <i>Journal of Skin Cancer</i> , 2019, 2019, 1-11.	0.5	16
5	Integrative molecular and clinical modeling of clinical outcomes to PD1 blockade in patients with metastatic melanoma. <i>Nature Medicine</i> , 2019, 25, 1916-1927.	15.2	541
6	Acute progressive neuropathyâ€“myositisâ€“myasthenia-like syndrome associated with immune-checkpoint inhibitor therapy in patients with metastatic melanoma. <i>Melanoma Research</i> , 2019, 29, 435-440.	0.6	23
7	Salvage therapy after failure from anti-PD-1 single agent treatment: A Study by the German ADOReg melanoma registry.. <i>Journal of Clinical Oncology</i> , 2019, 37, 9505-9505.	0.8	12
8	Treatment-related hemophagocytic lymphohistiocytosis secondary to checkpoint inhibition with nivolumab plus ipilimumab. <i>European Journal of Cancer</i> , 2018, 93, 150-153.	1.3	43
9	PD-L1 status does not predict the outcome of BRAF inhibitor therapy in metastatic melanoma. <i>European Journal of Cancer</i> , 2018, 88, 67-76.	1.3	15
10	The mTOR-inhibitor Sirolimus decreases the cyclosporine-induced expression of the oncogene ATF3 in human keratinocytes. <i>Journal of Dermatological Science</i> , 2018, 92, 172-180.	1.0	8
11	Programmed cell death protein-1 (PD-1) inhibitor therapy in patients with advanced melanoma and preexisting autoimmunity or ipilimumab-triggered autoimmunity. <i>European Journal of Cancer</i> , 2017, 75, 24-32.	1.3	162
12	Prognostic factors and treatment outcomes in 444 patients with mucosal melanoma. <i>European Journal of Cancer</i> , 2017, 81, 36-44.	1.3	76
13	Effects of mammalian target of rapamycin inhibitors on cytokine production and differentiation in keratinocytes. <i>Experimental Dermatology</i> , 2016, 25, 775-782.	1.4	12
14	Allele frequencies of BRAF<i>V600</i> mutations in primary melanomas and matched metastases and their relevance for BRAF inhibitor therapy in metastatic melanoma. <i>Oncotarget</i> , 2015, 6, 37895-37905.	0.8	26
15	Is there a therapeutic benefit of complete lymph node dissection in melanoma patients with low tumor burden in the sentinel node?. <i>Melanoma Research</i> , 2014, 24, 454-461.	0.6	42
16	Nonâ€“melanoma skin cancer is reduced after switch of immunosuppression to mTORâ€“inhibitors in organ transplant recipients. <i>JDDG - Journal of the German Society of Dermatology</i> , 2014, 12, 480-488.	0.4	26
17	Reply to N. Rompoti et al. <i>Journal of Clinical Oncology</i> , 2013, 31, 3845-3846.	0.8	1
18	Serious Skin Toxicity With the Combination of BRAF Inhibitors and Radiotherapy. <i>Journal of Clinical Oncology</i> , 2013, 31, e220-e222.	0.8	70

#	ARTICLE	IF	CITATIONS
19	S3â€œGuideline â€œDiagnosis, therapy and followâ€œup of melanomaâ€œ short version. JDDG - Journal of the German Society of Dermatology, 2013, 11, 563-602.	0.4	63
20	micro<scp>RNA</scp>â€œ21 is upregulated in malignant melanoma and influences apoptosis of melanocytic cells. Experimental Dermatology, 2012, 21, 509-514.	1.4	66
21	Reply to assessment of capsular melanoma cell deposits in sentinel lymph nodes. Cancer, 2011, 117, 2821-2821.	2.0	0
22	Parameters Predicting Prognosis in Melanoma Sentinel Nodes. Journal of Clinical Oncology, 2011, 29, 3588-3590.	0.8	7
23	Comparison of classification systems in melanoma sentinel lymph nodesâ€œAn analysis of 697 patients from a single center. Cancer, 2010, 116, 3178-3178.	2.0	44
24	MicroRNAâ€œ15b represents an independent prognostic parameter and is correlated with tumor cell proliferation and apoptosis in malignant melanoma. International Journal of Cancer, 2010, 126, 2553-2562.	2.3	168
25	Anal Mucosal Melanoma with <i>KIT</i>-Activating Mutation and Response to Imatinib Therapy â€œ Case Report and Review of the Literature. Dermatology, 2010, 220, 77-81.	0.9	74
26	Criteria in Sentinel Lymph Nodes of Melanoma Patients that Predict Involvement of Nonsentinel Lymph Nodes. Annals of Surgical Oncology, 2008, 15, 1723-1732.	0.7	55
27	Prognostic Significance of Isolated HMB45 or Melan A Positive Cells in Melanoma Sentinel Lymph Nodes. American Journal of Surgical Pathology, 2007, 31, 1175-1180.	2.1	66
28	Autoimmunity as a prognostic factor in melanoma patients treated with adjuvant lowâ€œdose interferon alpha. International Journal of Cancer, 2007, 121, 2562-2566.	2.3	36
29	Therapeutic use of erythropoietin in dermatooncology. JDDG - Journal of the German Society of Dermatology, 2007, 5, 280-285.	0.4	0